Voyager Awarded New Mission Management Contract With Exobiosphere

Key Terms

international space station technical

A permanently crewed laboratory and living platform orbiting Earth, assembled and operated by multiple countries to conduct scientific experiments, test space technologies, and host commercial activities. For investors, it matters because work done there can validate new products, create markets for space-based services, attract government and private contracts, and accelerate technologies that spin off to Earth — think of it as a shared, high‑cost testbed and partnership hub that can de‑risk and showcase future commercial opportunities.

microgravity technical

Microgravity is a condition where objects experience almost no net weight because they are in continuous free-fall, such as aboard orbiting spacecraft; think of passengers feeling weightless in a smoothly falling elevator. For investors, microgravity matters because it enables scientific experiments and manufacturing processes that behave very differently than on Earth, potentially creating novel drugs, materials, or technologies, changing development timelines, costs, market opportunities and regulatory considerations.

payload technical

Payload is the active substance or cargo carried by a delivery system — for example, the drug molecule attached to an antibody, the gene in a viral vector, or instruments aboard a satellite. Investors care because the payload determines the product’s therapeutic effect, safety profile, manufacturing complexity, regulatory hurdles and commercial value; like the contents of a sealed package, the delivery method matters, but the payload is what buyers ultimately want.

brightfield medical

Brightfield is a standard light-microscopy method where specimens are lit from below so cells or structures appear darker against a bright background, similar to holding a thin leaf up to a flashlight to reveal its veins. Investors care because it’s a basic, widely used lab tool for routine inspection, product development and quality control in diagnostics and life-science firms; demand for microscopes, consumables and supporting services often depends on its continued use.

fluorescence microscopy medical

A laboratory imaging technique that uses special dyes or markers that glow under particular light so tiny structures — cells, proteins or materials — become visible, like using colored highlighters to show details on a dark page. Investors care because it’s a core tool for showing whether a drug, diagnostic test or manufacturing process is working; clear microscopy results can reduce scientific risk, support regulatory filings and influence a company’s value.

luminescence medical

Luminescence is light produced by a material or reaction without heat, like a glow stick or firefly producing light when chemicals interact. For investors, it matters because many medical tests, lab instruments, sensors and specialty products rely on this glow to detect molecules, measure reactions or enable new devices; improvements or patents in luminescence technology can change a company’s product value, market position and regulatory prospects.

low earth orbit technical

Low Earth orbit (LEO) is the region of space close to Earth, roughly from about 160 to 2,000 kilometers above the surface, where satellites and spacecraft circle the planet quickly—think of it as a busy highway just overhead. It matters to investors because many communications, imaging and data services rely on satellites in LEO; their shorter lifespans, lower launch costs, crowded lanes and debris risks directly affect the cost, revenue potential and operational risks of companies that build, launch or use these satellites.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Exobiosphere to Launch First Automated Drug Screening Mission in Orbit

DENVER & LUXEMBOURG--(BUSINESS WIRE)-- Voyager Technologies (NYSE: VOYG) and Exobiosphere today announced a mission management contract on the International Space Station (ISS) that marks a concrete step toward making automated biological research in microgravity commercially accessible to researchers, agencies, pharmaceutical and biotech partners.

“Our mission management services exist to build a clear path for innovative ideas to become a reality in space,” said Matt Magaña, president of Space, Defense and National Security, Voyager. “Facilitating this access to the ISS is critical to improving life here on Earth, and irrespective of platform, we have a proven path to do that.”

Under the contract, Voyager Technologies Europe will serve as mission integrator for the Orbital High-Throughout Screener (OHTS), Exobiosphere’s miniaturized platform aboard the ISS. Voyager will also provide project management support, including safety and verification to the NASA Safety Review standards, integration aboard the ISS and coordination of on-orbit operations for the installed OTHS payload.

“Our agency, research, and biotech partners have been telling us the same thing: they need high-throughput automated systems, increased access, and a higher cadence," said Kyle Acierno, CEO of Exobiosphere. “Hardware on station means we can serve partners continuously and start building the operational track record that opens the door to pharma and biotech at scale.”

Built for repeat use, the OHTS architecture is modular: samples and consumable elements can be exchanged between campaigns, giving pharmaceutical and biotech clients a continuous pipeline of experiments without requiring a new hardware deployment each time. Follow-on contracts are expected.

“OHTS is the first payload of its kind, capable of running over 2,000 simultaneous drug screening samples in a single mission, with integrated brightfield and fluorescence microscopy, luminescence reading, and fully autonomous media and reagent exchange,” said Olivia Borgue, co-founder and director of Engineering, Exobiosphere. “Having Voyager’s expertise in ISS integration and mission management by our side means we can focus entirely on advancing the science and delivering real value to our clients.”

The contract reinforces Voyager’s track record of facilitating access to low-Earth orbit and advances Exobiosphere’s mission to improve life on Earth through microgravity research.

“Voyager Technologies Europe is committed to supporting Europe’s growing ambitions in Low Earth Orbit by working with International Space Station capabilities today and preparing for the next phase of commercial space stations with Starlab,” said Mattia Pianorsi, managing director, Voyager Technologies Europe. “Our presence in Europe allows us to work closely with regional partners and institutions, turning advanced concepts into operational missions.”

About Voyager Technologies

Voyager Technologies is a defense and space technology company committed to advancing and delivering transformative, mission-critical solutions. By tackling the most complex challenges, Voyager aims to unlock new frontiers for human progress, fortify national security, and protect critical assets from ground to space. For more information visit: voyagertechnologies.com and follow on LinkedIn and X.

About Exobiosphere

Exobiosphere is a space biotech company specializing in accelerated drug discovery. Its mission is to extend and improve life on Earth and in space by using microgravity as a new dimension for biology, enabling therapies that are hard or impossible to develop in a standard laboratory environment. Exobiosphere works to make space a routine and essential part of the biomedical research and development pipeline. For more information visit Exobiosphere.com and follow us on LinkedIn

Voyager Technologies Cautionary Statement Concerning Forward-Looking Statements

This press release contains “forward-looking statements.” All statements, other than statements of historical fact, including those with respect to Voyager Technologies, Inc.’s (the “Company’s”) mission statement and growth strategy, are “forward-looking statements.” Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve many risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, the Company’s ability to sustain and generate growth, ability to generate a sustainable order rate for its products and services and develop new technologies to meet customer needs, general economic conditions and conditions affecting the industries in which the Company operates, the uncertainty of regulatory requirements and approvals, and the ability to obtain necessary financing on acceptable terms or at all. Readers should not place any undue reliance on forward-looking statements since they involve these known and unknown uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513946939/en/

Media Contacts
Nora Ellish, The 10 Group USA for Voyager Technologies, Nora.Ellish@the10group.com
Ilaria Ferrari, Exobiosphere, ilaria.ferrari@exobiosphere.com

Source: Voyager Technologies